Cocrystal Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	June 30, 2024	December 31, 2023
(unaudited)
Assets
Current assets:
Cash	$18,143	$26,353
Restricted cash	75	75
Tax credit receivable	1,077	890
Prepaid expenses and other current assets	365	1,773
Total current assets	19,660	29,091
Property and equipment, net	211	271
Deposits	29	46
Operating lease right-of-use assets, net (including $11 and $42 to related party)	1,673	1,851
Total assets	$21,573	$31,259
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$2,403	$3,022
Current maturities of operating lease liabilities (including $10 and $42 to related party)	251	240
Total current liabilities	2,654	3,262
Long-term liabilities:
Operating lease liabilities (including $0 and $0 to related party)	1,529	1,613
Total long-term liabilities	1,529	1,613
Total liabilities	4,183	4,875
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock, $0.001 a par value: 100,000 and 150,000 shares authorized as of June 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of June 30, 2024 and December 31, 2023	10	10
Additional paid-in capital	342,593	342,288
Accumulated deficit	(325,213)	(315,914)
Total stockholders’ equity	17,390	26,384
Total liabilities and stockholders’ equity	$21,573	$31,259

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.